Introduction: The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib were compared in the multicenter, international, randomized, head-to-head phase 2b LUX-Lung 7 trial for first-line treatment of advanced EGFR mutation-positive NSCLCs. Afatinib and gefitinib costs and patients' outcomes in France were assessed.
Introduction
Lung cancer is the most common cause of cancerrelated deaths in France and the world, with 39,495 new lung cancers diagnosed in France in 2012.
1 NSCLCs represent 85% of all new lung cancers worldwide, and they carry substantial clinical and economic burdens for health care systems. 2 In France, the average cost of managing a patient with NSCLC was approximately V20,000 in 2000 and has since risen fourfold. 3 Targeted therapies to treat advanced NSCLCs with an EGFR gene mutation (EGFR mutation-positive NSCLCs) are now well established. For these patients, tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, are approved first-line therapies. As demonstrated by the results of several randomized trials, 4 these agents obtain better response rates, longer progression-free survival (PFS), better tolerance, and superior quality of life (QoL) than platinum-based chemotherapy. TKIs are also cost-effective compared with platinum-doublet chemotherapy. A 2013 study comparing the costeffectiveness of erlotinib and afatinib, with that of cisplatin-pemetrexed as first-line treatment for advanced EGFR mutation-positive NSCLCs in the United States on the basis of data from two large randomized phase III trials showed that the two TKIs were dominant compared with chemotherapy. 5 Clinical and resource use data collected during the EURTAC trial also indicated erlotinib's favorable cost-effectiveness ratio compared with that of platinum-doublet chemotherapy in a white population harboring EGFR mutations. 3 The LUX-Lung 7 trial was the first prospective, global, randomized, head-to-head trial comparing two EGFRdirected therapies (afatinib versus gefitinib) as firstline therapy for EGFR mutation-positive NSCLCs. 6 In that trial, afatinib significantly prolonged PFS compared with gefitinib, with a numerical overall survival (OS) trend in favor of afatinib that was consistent across all prespecified subgroups, including those with exon 19 deletion (del19) or exon 21 L858R mutation (L858R). This study was undertaken to assess afatinib and gefitinib costs, with evaluation of the entire EGFR mutation-positive population's outcomes and those of each subgroup (del19 or L858R).
Methods

LUX-Lung 7 Trial
Data from LUX-Lung 7, a head-to-head phase 2b trial comparing first-line afatinib with gefitinib for patients with advanced EGFR mutation-positive NSCLC, were analyzed. 6 Treatment-naive patients with advancedstage EGFR mutation-positive NSCLCs and a common mutation (del19 or L858R) were randomly assigned (1:1) to receive afatinib (40 mg/day) or gefitinib (250 mg/day) until disease progression, or beyond if deemed beneficial by the investigator. PFS, time to treatment failure, and OS were the coprimary end points. Secondary end points included response rate, adverse events (AEs), and QoL. Afatinib achieved significantly longer median PFS than gefitinib (11. The base case scenario is based on the LUX-Lung 7 trial intention-to-treat (ITT) population comprising patients with common EGFR mutation-positive NSCLCs. Analyses of additional scenarios were simulated separately for the del19 and L858R subgroups.
Model Structure
A partitioned survival model was created with the following parameters: patients transitioned through three health states: progression-free (PF) phase, progressive disease (PD), and death (Fig. 1) ; a 10-year time horizon was chosen to cover extrapolated survival curves based on clinical trial data; and the treatment cycle lasted 1 month.
First-line oral afatinib or gefitinib was followed, for eligible patients, by combination pemetrexed-cisplatin chemotherapy, which is the most frequent second-line choice in France after a first-line TKI. After second-line progression, patients were assumed to receive best supportive care (BSC). Durations of the PF and PD phases were calculated using the area under the survival curve method. The entire PD period was calculated on the basis of the difference between the OS and PFS derived from the parametric survival models. The portion of the PD period that patients were assumed to spend undergoing active second-line therapies was based on published median second-line PFS durations. 7 The rest of the time in the PD period was assumed to be spent receiving BSC, which was calculated by subtracting the time of second-line treatment from the total PD time for each arm.
Separate OS and PFS data were available from the LUX-Lung 7 trial (Table 1) ; their extrapolations were based on a Weibull specification, which had the best goodness of fit to the Kaplan-Meier survival data according to Akaike's information criterion.
Utilities and Costs
Only direct medical costs were considered and, when possible, the production cost approach was retained according to the French National Health Authority recommendations versus National Sickness Fund fee schedules and prices. 8 Drug acquisition costs for the TKIs dispensed in retail pharmacies were taken from official list prices. Pemetrexed is administered only in a hospital setting and is reimbursed in addition to the diagnosis-related group (DRG) price. Because docetaxel is included in DRG costs, only the DRG cost was taken into account. The BSC cost was obtained from published data. 9 For doctors' fees, we used actual fees charged to patients, because private physicians in France can charge additional fees exceeding the National Health Insurance (NHI) fee schedules. For outpatient visits to public hospitals, we used published cost accounting data providing the full cost of a visit to an outpatient department. Outpatient care monitoring and diagnosis costs (laboratory tests and imaging) were taken from the so-called NHI conventional fee schedules. A panel of six oncologists completed a questionnaire to estimate the resources used to manage patients during each cycle beyond treatment costs. The cost of AE management was calculated by using the rates and durations reported in the LUX-Lung 7 trial. They were combined with the standardized NHI costs for hospital care weighted according to the relative share of public and private hospitals ( Table 2) .
Utility data came from several sources. French EuroQol five-dimension questionnaire data were available from the LUCEOR 2 study for patients with stage IIB/IV NSCLCs for the following states: first-and second-line PF phase, first-and second-line PD, and BSC.
10 Utility values were assumed to be the same across therapies. Thus, QoL differences across treatments arose from different AE profiles. AE disutilities were derived from data collected in LUX-Lung trials and one publication. 11 Because disutility data were not available for all AEs identified in the trials, we chose to restrict inputs to specific TKI-associated grade 3/4 AEs whose frequencies exceeded 5% in both treatment arms (i.e., rash, diarrhea, and fatigue). We assumed that severe AEs would require hospital care. Using the National Discharge Database, we identified AEs by their International Classification of Diseases, Tenth Revision, codes and their respective DRGs, with their tariffs according to severity levels. Data on AE durations, which were available from LUX-Lung 3, were used to compute related disutilities but not costs. Costs and benefits were discounted at a rate of 4%, according to the French National Health Authority guidelines. 12 
Sensitivity Analyses
One-way sensitivity and probabilistic (1000 simulations) analyses were run for each scenario. For the former, when available, the lower and upper CI limits were used. The following parameters were varied: PD cost per month, BSC cost per month, utility and disutility scores, discount effect and rate, duration, and AE frequencies and costs. The discount rate was allowed to vary from 0% to 6%. Lower and upper AE cost values were the AE's lowest and highest DRG costs for the identified International Classification of Diseases, Tenth Revision, code. High and low resource use values for management costs beyond drug treatment came from the expert panel questionnaire. Unit costs of drugs, laboratory tests, imaging, and physician visits were considered to be fixed. For the pemetrexed-cisplatin combination, there could be three or six cycles and body-surface area was allowed to vary between 1.75 and 1.95 m 2 , with a central value of 1.85 m 2 . Uncertainty around the OS and PFS HRs for afatinib compared with those for pemetrexed-cisplatin in the first-line model was assessed by using the Cholesky decomposition to allow simultaneous assessment of uncertainty for all parameters of the parametric survival models. b Distributions were used for utility values and AE frequencies.
Results
Costs, QALYs, and ICERs
For the ITT population and the del19 and L858R subgroups, respectively, afatinib instead of gefitinib provided an extra 0.249, 0.257, and 0.247 life-years gained and 0.170, 0.171 and 0.174 quality-adjusted life-years (QALYs).
For all scenarios simulated, mean direct costs were higher for afatinib than for gefitinib, with incremental cost-effectiveness ratios (ICERs) for the ITT population and del19 and L858R subgroups of V7697, V6668, and V9148, respectively, over the 10-year time horizon. AE costs accounted for less than 3% of the total costs for both treatment arms and all scenarios. The ICERs for afatinib versus gefitinib for the ITT population, del19 subgroup, and L858R subgroup, respectively, were V45,211, V38,970, and V52,518 (Table 3) .
Sensitivity Analyses
Deterministic sensitivity analyses showed that utility in PF had the highest impact on model outcomes for both arms. When the afatinib arm utility in PF varied from 0.66 to 0.72, the relative ICERs for the ITT population, del19 subgroup, and L858R subgroup, respectively, were V57,823 and V37,116, V50,291 and V31,809, and V65,830 and V43,684. The first-line PF management costs for both treatment arms had the second greatest impact on cost-effectiveness for all scenarios. The other parameters that affected the ICER were discounting, monthly BSC costs, and the cost of grade 3 diarrhea. QALYs, quality-adjusted life-years; ICER, Incremental cost-effectiveness ratio; ITT, intention-to-treat; PFS, progression-free survival; OS, overall survival; del19, EGFR exon 19 deletion; L858R, EGFR exon 21 L858R.
The acceptability curves showed that afatinib had a 100% probability of being cost-effective at a willingnessto-pay (WTP) threshold for patients with common EGFR mutations and those in the del19 or L858R subgroups of V70,000, V60,000, and V75,000, respectively (Figs. 2 and 3 , and Supplementary Table) .
Discussion
The results of this analysis showed that the ICERs of first-line afatinib versus gefitinib for the ITT population of common EGFR mutations and those in the del19 and L858R subgroups were V45,211, V38,970, and V52,518, respectively.
The results of several clinical trials showed the PFS superiority of EGFR TKIs such as afatinib, gefitinib, and erlotinib over standard chemotherapy. Several costeffectiveness studies also found favorable ICERs for using a first-line TKI to treat EGFR mutation-positive NSCLCs compared with that of standard first-line chemotherapy. When the EURTAC trial's data were used, first-line erlotinib for whites with EGFR mutation-positive NSCLCs was cost saving and yielded a 0.117-QALY gain. Probabilistic sensitivity analysis results indicated that given a WTP of at least V90,000/ QALY, the probability that the first-line erlotinib strategy would be cost-effective was 100% in France, 100% in Italy, and 99.8% in Spain. In China, a cost-effectiveness analysis based on a Markov model adopting the perspective of the Chinese health care system and using data from the OPTIMAL trial, which took place in 22 Chinese centers, found an incremental QALY of 0.56 with erlotinib compared with chemotherapy, for an ICER range of $58,584.57 to $336,404.20. At a WTP threshold of $96,884, erlotinib had a 50% probability of being costeffective. The findings of another recently published study comparing the cost-effectiveness of first-line erlotinib, afatinib, or cisplatin-pemetrexed for advanced EGFR mutation-positive NSCLCs in the United States based on data from EURTAC and LUX-Lung 3 trials, showed that the two TKIs were dominant compared with chemotherapy.
LUX-Lung 7 was the first head-to-head randomized trial to compare two EGFR TKIs in patients with NSCLC. 13 A network meta-analysis assessed the relative efficacies of afatinib, gefitinib, and erlotinib in that setting by using data from eight trials conducted on populations with EGFR mutation-positive NSCLC.
14 Afatinib significantly improved PFS versus gefitinib or erlotinib in patients with common EGFR mutations (HR for afatinib versus gefitinib ¼ 0.43 and 95% CI: 0.24-0.75 as opposed to HR for afatinib versus erlotinib ¼ 0.60 and 95% CI: 0.39-0.91). Results also favored afatinib in the individual EGFR mutation subgroups (del19 and L858R), although only the comparison of afatinib and gefitinib in the del19 subgroup was statistically significant. On the basis of this network meta-analysis, afatinib appears to be the best treatment option when compared with the reversible EGFR TKIs erlotinib and gefitinib as first-line treatment for NSCLC with common EGFR mutations, particularly the del19 mutation. 14 Our study had some limitations. First, maintenance therapy, which is a possible option for nonprogressing patients after platinum-doublet treatment, was not included in this cost-effectiveness analysis.
1 Another limitation was that in real life, patients may receive two or three consecutive lines of treatments, which our model summarized as BSC. Finally, we used data from patients managed in a clinical trial, who may differ from the general NSCLC population. Moreover, management costs vary from one health care system to another, and prudence is required when extrapolating these results to other countries.
In France, although cost-effectiveness analysis has been mandatory since October 2013 for drugs claimed to have innovative status, no official WTP threshold leading to recommendations on coverage exists, unlike in the United Kingdom. The WHO-recommended conventional benchmark is an acceptable ICER value range of one to three gross national products per capita, which would mean 2015 values of V32,735 to V98,205 in France. The ICERs for all tested scenarios fell within that range, and targeting del19 would lead to a robust cost-effectiveness ratio of 40,000V/QALY.
Conclusion
On the basis of the results of the head-to-head LUX-Lung 7 trial results, with an ICER ranging between V38,970/QALYs and V52,518/QALYs in the French context, first-line afatinib for patients with EGFR mutation-positive NSCLCs is cost-effective compared with gefitinib.
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